BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
Purpose: To evaluate the effects of BRAF inhibition on the tumor microenvironment in
patients with metastatic melanoma. Experimental Design: Thirty-five biopsies were collected …
patients with metastatic melanoma. Experimental Design: Thirty-five biopsies were collected …
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Targeted therapy against the BRAF/mitogen-activated protein kinase (MAPK) pathway is a
promising new therapeutic approach for the treatment of melanoma. Treatment with …
promising new therapeutic approach for the treatment of melanoma. Treatment with …
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis
JH Lee, JW Choi, YS Kim - British Journal of Dermatology, 2011 - academic.oup.com
Background There have been conflicting data regarding the prevalence and
clinicopathological characteristics of BRAF and NRAS mutations in primary cutaneous …
clinicopathological characteristics of BRAF and NRAS mutations in primary cutaneous …
Influences of BRAF inhibitors on the immune microenvironment and the rationale for combined molecular and immune targeted therapy
SM Reddy, A Reuben, JA Wargo - Current oncology reports, 2016 - Springer
The identification of key driver mutations in melanoma has led to the development of
targeted therapies aimed at BRAF and MEK, but responses are often limited in duration …
targeted therapies aimed at BRAF and MEK, but responses are often limited in duration …
[HTML][HTML] What happens to the immune microenvironment after PD-1 inhibitor therapy?
Q Wang, B **e, S Liu, Y Shi, Y Tao, D **ao… - Frontiers in …, 2021 - frontiersin.org
The fruitful results of tumor immunotherapy establish its indispensable status in the
regulation of the tumorous immune context. It seems that the treatment of programmed cell …
regulation of the tumorous immune context. It seems that the treatment of programmed cell …
[HTML][HTML] Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation
T Shibata, A Kokubu, M Miyamoto, Y Sasajima… - The American journal of …, 2011 - Elsevier
Melanoma is the most deadly tumor of the skin, and systemic therapies for the advanced
stage are still limited. Recent genetic analyses have revealed the molecular diversity of …
stage are still limited. Recent genetic analyses have revealed the molecular diversity of …
Kita driven expression of oncogenic HRAS leads to early onset and highly penetrant melanoma in zebrafish
C Santoriello, E Gennaro, V Anelli, M Distel, A Kelly… - PloS one, 2010 - journals.plos.org
Background Melanoma is the most aggressive and lethal form of skin cancer. Because of the
increasing incidence and high lethality of melanoma, animal models for continuously …
increasing incidence and high lethality of melanoma, animal models for continuously …
BRAF (V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency
DS Hong, L Vence, G Falchook, LG Radvanyi, C Liu… - Clinical cancer …, 2012 - AACR
Purpose: An intact immune system likely contributes to the outcome of treatment and may be
important for clearance of drug-resistant tumor cells and for prevention of recurrence …
important for clearance of drug-resistant tumor cells and for prevention of recurrence …
Altered molecular pathways in melanocytic lesions
M Scatolini, MM Grand, E Grosso… - … Journal of Cancer, 2010 - Wiley Online Library
To identify gene expression changes in melanocytic lesions, biopsies from 18 common nevi
(CMN), 11 dysplastic nevi (DN), 8 radial and 15 vertical growth phase melanomas (RGPM …
(CMN), 11 dysplastic nevi (DN), 8 radial and 15 vertical growth phase melanomas (RGPM …
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab
V Shahabi, G Whitney, O Hamid, H Schmidt… - Cancer Immunology …, 2012 - Springer
Ipilimumab, a fully human monoclonal antibody against cytotoxic T lymphocyte antigen-4,
has demonstrated significant improvement in overall survival in previously treated advanced …
has demonstrated significant improvement in overall survival in previously treated advanced …